Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stocks rose Wednesday on promising new COVID-19 vaccine data from Moderna Therapeutics, although much of the optimism is outpacing the science.

Axios Re:Cap digs into what Moderna said, what it didn't say, and what comes next in the vaccine race with Richard Besser, former acting director of the CDC and current CEO of the Robert Wood Johnson Foundation.

Go deeper

Oct 22, 2020 - Health

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.

Updated Oct 22, 2020 - World

France becomes 2nd Western European country to top 1M coronavirus cases

French President Emmanuel Macron at the Seine Saint Denis prefecture headquarters in Paris, on Tuesday. Photo: Ludovic Marin/POOL/AFP via Getty Images

France has become the second country in Western Europe to surpass 1 million COVID-19 cases, Johns Hopkins University data shows

The big picture: France had reported 1,000,369 cases and 34,075 deaths from the coronavirus by Thursday morning, per JHU. French President Emmanuel Macron declared a state of health emergency and imposed a curfew on virus hot spots earlier this month. Spain on Wednesday became the first Western European nation to top 1 million cases.

Updated 18 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: WHO: AstraZeneca vaccine must be evaluated on "more than a press release."
  2. Politics: Supreme Court backs religious groups on New York COVID restrictions.
  3. World: Thailand, Philippines sign deal with AstraZeneca for vaccine.
  4. Economy: Safety nets to disappear in December Black Friday shopping across the U.S., in photosAmazon hires 1,400 workers a day throughout pandemic.
  5. Education: National standardized tests delayed until 2022.